Challenge of hepatitis C in Egypt and hepatitis B in Mauritania

doi:10.4254/wjh.v10.i9.549

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5904)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-3) series.

Item

Count

PDF

474

WORD

268

HTML

2928

Tables (1-3)

233

Sum=3903

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

974

Download

1027

Sum=2001

Sep 27, 2018 (publication date) through Nov 29, 2024

Times Cited of This Article

Times Cited (9)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Hepatol. Sep 27, 2018; 10(9): 549-557
Published online Sep 27, 2018. doi: 10.4254/wjh.v10.i9.549

Table 2 Direct-acting antiviral regimens available to treat hepatitis C virus genotype 4

¹Combination regimen[43,44]	Duration (wk)
Sofosbuvir-ledipasvir	12
Sofosbuvir-velpatasvir	12
Glecaprevir-pibrentasvir	8 (without cirrhosis)
Glecaprevir-pibrentasvir	12 (with cirrhosis)
Sofosbuvir-velpatasvir-voxilaprevir	12
Ombitasvir-paritaprevir-ritonavir ± ribavirin	12
Elbasvir-grazoprevir ± ribavirin	12-16
Elbasvir-grazoprevir	12 (treatment naïve)
Elbasvir-grazoprevir + ribavirin	16 (treatment experienced)
Sofosbuvir + ribavirin	24
Sofosbuvir + daclatasvir ± ribavirin	12
Sofosbuvir + simeprivir ± ribavirin	12-24

¹The information from the table is from the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) hepatitis C virus guidelines.

Citation: Raad II, Chaftari AM, Torres HA, Ayoub EM, Narouz LI, Bartek J, Hachem R. Challenge of hepatitis C in Egypt and hepatitis B in Mauritania. World J Hepatol 2018; 10(9): 549-557
URL: https://www.wjgnet.com/1948-5182/full/v10/i9/549.htm
DOI: https://dx.doi.org/10.4254/wjh.v10.i9.549